Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.
about
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumorsDPP4 in DiabetesTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsClinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patientsDipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retentionGenetics of type 2 diabetes: insights into the pathogenesis and its clinical application.The regulatory role of DPP4 in atherosclerotic disease.Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress.Effects of Dipeptidyl Peptidase-4 Inhibition with MK-0431 on Syngeneic Mouse Islet TransplantationGlucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice.Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic α cells to cytokine-induced apoptosis as compared to β cellsPreventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null miceAmelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.Incretin therapy and islet pathology: a time for caution.Retinoblastoma tumor suppressor protein in pancreatic progenitors controls α- and β-cell fate.Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3Incretin hormones and beta-cell mass expansion: what we know and what is missing?Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Rb and p107 are required for alpha cell survival, beta cell cycle control and glucagon-like peptide-1 action.DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.Combined Oral Administration of GABA and DPP-4 Inhibitor Prevents Beta Cell Damage and Promotes Beta Cell Regeneration in MiceEfficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents:TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals.β-cell preservation and regeneration for diabetes treatment: where are we now?Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.Evaluation of hypoglycemic and antioxidative effects of synthesized peptide MC62.Saxagliptin Induces β-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1α In Vivo and In Vitro.Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.Sitagliptin protects proliferation of neural progenitor cells in diabetic mice.Inhibition of DPP-4 Activity and Neuronal Atrophy with Genistein Attenuates Neurological Deficits Induced by Transient Global Cerebral Ischemia and Reperfusion in Streptozotocin-Induced Diabetic Mice.Effects of subchronic acrylamide treatment on the endocrine pancreas of juvenile male Wistar rats.Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice.Prion protein modulates glucose homeostasis by altering intracellular iron.
P2860
Q24598747-8E63179B-44E3-46A1-8DEF-5644A9D13187Q26797335-9309B8BB-8F51-419C-BED5-C12D9398A00AQ27021870-FB4A1590-A85A-4E86-A6C7-D0E52705F227Q28083144-729A016D-C3DF-4087-AB85-6616EA97E17DQ30717371-B4B08180-E624-4893-85F7-668EC6EDC8EDQ33593963-AB678B23-0CED-42BA-A9D8-99CEAB3B10F2Q33805518-36613838-97CE-48A3-9190-302B51240AADQ33812543-F0E15902-A19A-40C5-923D-EDE6B7B3760BQ34069011-4882879B-AE94-48C1-AC96-EAA47FE675E0Q34247469-64879CBA-77F2-4778-BD73-1FB9DCA313E0Q34273302-A87070B5-6D29-4E79-96D8-4F22C4C5C964Q34566878-B9858D1D-E793-4DF1-A4A0-B61F580CC921Q34963221-CFC07A76-D4F3-43AF-8614-68027ADC2817Q35852679-8EFE1363-4E58-4A9F-B94F-02A6E05E6C00Q36822640-D5DA1CDC-C1A8-4C30-A3B3-5D63B0475AC0Q37015080-93BE7D9B-0B73-48E0-A630-EEFFF41FF4EAQ37157315-6E43BFFF-100F-4F89-AB44-2806012B29DBQ37532382-294107CC-088E-4F35-B9B2-BF8CDB7FE9C1Q38108631-998C1D61-55A7-436B-A11C-8F4D9A3E345CQ38163894-EF901827-7F87-4FCD-9F5B-5289F4F4381BQ38205588-9BB96C06-C1E3-46AC-865B-9998E5D7747EQ38447564-08672863-B403-43CB-ABE5-60AA5A88079EQ38922177-DBE8A3ED-CE20-4EF8-887D-EF3F197CE130Q40181768-9730D143-F55B-49F2-A7A1-44E04371D6F2Q41094748-7845FED9-F182-4BAD-8F88-992FB66D870BQ41097981-681D0CD1-99D9-4B1C-92F4-B44B5E729AE9Q42511575-33E452EB-7EDD-43C0-ACCB-478CBF8791BCQ42535316-EB3B08CA-BC47-43DE-91C2-BC5B135558CAQ42876331-5592E2BB-E15E-4888-8139-F8BD4DA06CEFQ44120755-9A45E4B6-F538-4356-82F6-685424A3B96DQ46475564-D029E72C-04C1-4856-88C5-F5428875CFC7Q46770130-94B66973-8EA5-439A-838E-0D3D88BCE26CQ47096334-E2C1C0F4-5C4A-4FFF-98D5-7D51C0B33576Q47697775-0E2C47F7-28D8-4110-94FA-AFD753076644Q48321628-30A41521-6ED6-4D9C-A7DB-F51B726CD46BQ48355450-D9A0A059-48E9-4E5D-BA86-61D968A9E6D0Q50106732-998AE806-DD95-4BF6-A938-EEACA2F7F595Q51359217-496608E6-85C2-4E6F-ADD0-A41FFE34215EQ55259443-A86B05DC-699B-434E-BB0E-9648DC0ACD0BQ55285231-5CFA4CAE-D3F5-407D-95C4-451F728338CB
P2860
Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Reduction of both beta cell de ...... ced model of diabetes in mice.
@en
Reduction of both beta cell de ...... ced model of diabetes in mice.
@nl
type
label
Reduction of both beta cell de ...... ced model of diabetes in mice.
@en
Reduction of both beta cell de ...... ced model of diabetes in mice.
@nl
prefLabel
Reduction of both beta cell de ...... ced model of diabetes in mice.
@en
Reduction of both beta cell de ...... ced model of diabetes in mice.
@nl
P2093
P2860
P1433
P1476
Reduction of both beta cell de ...... ced model of diabetes in mice.
@en
P2093
H Sakagami
T J Kieffer
T Yanagimachi
Y Takiyama
P2860
P2888
P304
P356
10.1007/S00125-011-2365-4
P577
2011-11-10T00:00:00Z